A Phase 2 interventional study of Enteric-Coated Cholestyramine (ECC) Capsule and Placebo in Short Bowel Syndrome, sponsored by Pharmascience Inc.. Terminated at 3 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-19.
Sponsored by Pharmascience Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Short Bowel Syndrome with a site in Poland — 3 open to participants now, 5 under way, 4 of them phase 3. Short Bowel Syndrome · Poland.
Among the 15 studies in Short Bowel Syndrome with a site in Poland, this one is the 14th largest by enrollment, is one of 2 that started in 2019, is one of 2 in phase 2, and was the 8th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →3 of the 15 studies in Short Bowel Syndrome with a site in Poland are open now. Recruiting first, the newest first:
VectivBio AG · Sites in Poland, United States, Argentina and 19 more countries
Ages 18+
Zealand Pharma · Sites in Poland, United States, Austria and 11 more countries
Ages 18–90
Hanmi Pharmaceutical Company Limited · Sites in Poland, United States, Belgium and 5 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 86 across the 15 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 6 most frequent:
Pharmascience Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Pharmascience Inc. has 1 study filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Short Bowel Syndrome with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05018286Phase 3VectivBio AGOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Short Bowel Syndrome with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A new Enteric-Coated Cholestyramine (ECC) capsule has been developed to manage diarrhea associated with Short Bowel Syndrome (SBS) in adults. The formulation is expected to release cholestyramine in the remaining segment of the small intestine in SBS patients, thus binding bile acids after fat digestion, but before induction of diarrhea in the colon. The delayed-release profile is also expected to help reduce the potential for drug-drug interactions occurring in the proximal small intestine. Two doses of ECC will be studied for efficacy, safety and tolerability in this Phase IIa trial.
A new Enteric-Coated Cholestyramine (ECC) capsule has been developed to manage diarrhea associated with Short Bowel Syndrome (SBS). SBS is usually caused by the significant resection or loss of function of the ileum, leading to reduced reabsorption of bile acids and subsequent osmotic diarrhea. The new ECC formulation could release cholestyramine in the remaining segment of the small intestine in SBS patients, delivering and binding bile acids before they induce diarrhea in the colon. The proposed advantages of this formulation are: a) to prevent drug-drug interactions in the proximal GI tract, b) to preserve the fat digestive properties of bile acids in the duodenum and 3) to offer a more palatable dosage form to patients. Moreover, since distal delivery of cholestyramine is expected to be more effective in diarrhea prevention/reduction in SBS, lower doses than the ones used with non-enteric coated cholestyramine may be sufficient. Two doses of ECC will be studied for efficacy, safety and tolerability in well-defined non fully-colectomized, adult SBS patients suffering from diarrhea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Stable SBS of:
Presence of stable chronic diarrhea during the 2-week screening diary period before randomization, as evidenced by completion of a screening diary demonstrating:
Female subjects must meet one of the following criteria:
a) Participant is of and agrees to use one of the accepted regimens from at least 30 days prior to the first study treatment administration through to at least 30 days after the last dose of the study treatment. An acceptable method of contraception includes one of the following:
b) Participants of non-childbearing potential, defined as surgically sterile (i.e. has undergone complete hysterectomy or bilateral oophorectomy) or is in a menopausal state (i.e. at least 1 year without menses prior to the first study drug administration) are eligible
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECC at the 1.7 g daily dose, administered BID (twice daily) as 2 capsules of ECC, plus 3 capsules of placebo, at least 30 minutes before breakfast and 2 capsules of ECC, plus 3 capsules of placebo at least 30 minutes before evening meal.
Drug: Enteric-Coated Cholestyramine (ECC) Capsule · Drug: Placebo
ECC at the 4.25 g daily dose, administered BID (twice daily) as 5 capsules of ECC at least 30 minutes before breakfast and 5 capsules of ECC at least 30 minutes before evening meal.
Drug: Enteric-Coated Cholestyramine (ECC) Capsule
Enteric-Coated Delayed Release Cholestyramine Capsules
Enteric-Coated Delayed Release Placebo Capsules
Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment
Change in the weekly frequency of bowel movements measured between baseline and the second week of treatment. Baseline is defined as the second week of screening for treatment period 1 and second week of washout for treatment period 2.
Time frame: Baseline and Week 2 of treatment (Days 8 to 14, and Days 36 to 42)
Total Number of Bowel Movements for the Whole 2-week Treatment Period
Time frame: Days 1 to 14 and Days 29 to 42
Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment
The BSFS classifies the form of human feces into seven categories (Type 1 to Type 7) based on stool shape and consistency. Types or scores of 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, 5 tending towards diarrhea, and 6 and 7 indicate diarrhea.
Time frame: Days 8 to 14, and Days 36 to 42
Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment
Time frame: Days 8 to 14, and Days 36 to 42
| Milestone | "Low" Dose ECC Regimen, Then "High" Dose ECC Regimen | "High" Dose ECC Regimen, Then "Low" Dose ECC Regimen |
|---|---|---|
| Started | 6 | 7 |
| Completed | 6 | 7 |
| Not completed | 0 | 0 |
| Milestone | "Low" Dose ECC Regimen, Then "High" Dose ECC Regimen | "High" Dose ECC Regimen, Then "Low" Dose ECC Regimen |
|---|---|---|
| Started | 6 | 7 |
| Completed | 6 | 7 |
| Not completed | 0 | 0 |
| Milestone | "Low" Dose ECC Regimen, Then "High" Dose ECC Regimen | "High" Dose ECC Regimen, Then "Low" Dose ECC Regimen |
|---|---|---|
| Started | 6 | 7 |
| Completed | 6 | 7 |
| Not completed | 0 | 0 |
Change in the weekly frequency of bowel movements measured between baseline and the second week of treatment. Baseline is defined as the second week of screening for treatment period 1 and second week of washout for treatment period 2.
| Weekly bowel movements | "Low" Dose ECC Regimen | "High" Dose ECC Regimen |
|---|---|---|
| Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment | -11.5 ± 11.38 | -13.4 ± 9.73 |
| Bowel movements | "Low" Dose ECC Regimen | "High" Dose ECC Regimen |
|---|---|---|
| Total Number of Bowel Movements for the Whole 2-week Treatment Period | 52.5 ± 20.12 | 55.1 ± 25.18 |
The BSFS classifies the form of human feces into seven categories (Type 1 to Type 7) based on stool shape and consistency. Types or scores of 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, 5 tending towards diarrhea, and 6 and 7 indicate diarrhea.
| Score on BSFS scale | "Low" Dose ECC Regimen | "High" Dose ECC Regimen |
|---|---|---|
| Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment | 3.6 ± 1.42 | 3.7 ± 1.76 |
| mg | "Low" Dose ECC Regimen | "High" Dose ECC Regimen |
|---|---|---|
| Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment | 72.9 ± 43.05 | 68.9 ± 53.19 |
Collected over From patient randomization to the end of study visit, approximately 44 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| "Low" Dose ECC Regimen | 0/13 (0%) | 0/13 (0%) | 3/13 (23.1%) |
| "High" Dose ECC Regimen | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Event | "Low" Dose ECC Regimen | "High" Dose ECC Regimen |
|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 1/13 | 1/13 |
| Oedema peripheralGeneral disorders | 1/13 | 1/13 |
| Pulpitis dentalInfections and infestations | 1/13 | 1/13 |
| C-reactive protein increasedInvestigations | 0/13 | 1/13 |
| HypokalaemiaMetabolism and nutrition disorders | 1/13 | 0/13 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/13 | 1/13 |
| Decreased appetiteMetabolism and nutrition disorders | 0/13 | 1/13 |
| Age, Continuous(years) | Intent-to-Treat (ITT Population) |
|---|---|
| Mean | 54.9 ± 15.98 |
| Sex: Female, Male(Participants) | Intent-to-Treat (ITT Population) |
|---|---|
| Female | 6 |
| Male | 7 |
| Race/Ethnicity, Customized(Participants) | Intent-to-Treat (ITT Population) |
|---|---|
| Asian | 0 |
| Black | 0 |
| Caucasian | 13 |
| Other | 0 |
| Region of Enrollment(participants) | Intent-to-Treat (ITT Population) |
|---|---|
| Poland | 13 |
| Body Mass Index (BMI)(kg/m^2) | Intent-to-Treat (ITT Population) |
|---|---|
| Mean | 24.1 ± 3.84 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Dec 2021, 26 months.
Results were first posted in Jul 2022, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cholestyramine Resin
Pharmascience Inc.